Further Information - Leica BIOSYSTEMS S-100 (EP32) Mode D'emploi

• Consult Federal, State or local regulations for disposal of any potentially toxic components.
• Minimize microbial contamination of reagents or an increase in non-specific staining may occur.
• Retrieval, incubation times or temperatures other than those specified may give erroneous results. Any such change must be
validated by the user.
Instructions for Use
S-100 (EP32) primary antibody is recommended for use on an automated BOND system in combination with either BOND Polymer
Refine Detection (DS9800) or BOND Polymer Refine Red Detection (DS9390). The recommended staining protocols for S-100 (EP32)
primary antibody are IHC Protocol F when using BOND Polymer Refine Detection and IHC Protocol J when using BOND Polymer Refine
Red Detection. Heat induced epitope retrieval is recommended using BOND Epitope Retrieval Solution 1 for 20 minutes.
Results Expected
Normal Tissues
Clone EP32 detects S-100 protein in the nucleus and cytoplasm of cells of neuroectodermal origin in a variety of tissues.
Immunoreactivity was observed in nerve fibres, dendritic cells, adipocytes and a percentage of macrophages, lymphocytes and plasma
cells.
Staining was also observed in parenchymal cells in the cerebrum and cerebellum, islets of Langerhans in pancreas, myoepithelial cells
of salivary glands, retinal cells of the eye and myoepithelial and ductal cells of the breast. (Total number of normal cases = 117)
Tumor Tissues
Clone EP32 stained 20/42 peripheral nerve tumours (including 10/12 malignant Schwannomas, 4/4 ganglioneuromas, 3/21 malignant
peripheral nerve sheath tumours, 3/4 neurofibromas and 0/1 primitive neuroectodermal tumours), 9/11 malignant melanomas. No
staining was detected in other various tumours including GI tract tumours (0/12), breast tumours (0/6), lung tumours (0/6), ovarian
tumours (0/3), hepatocellular carcinomas (0/3), cervical tumours (0/3), endometrial tumours (0/3), bladder tumours (0/2), kidney clear
cell carcinomas (0/2), prostate adenocarcinomas (0/1), prostate hyperplasia (0/1), and squamous cell carcinoma of the skin (0/1). (Total
number of abnormal cases evaluated = 96)
S100 (EP32) is recommended for the detection of S-100 B protein in normal and neoplastic tissues, as an adjunct to
conventional histopathology using non-immunologic histochemical stains.
Product Specific Limitations
S-100 (EP32) has been optimized at Leica Biosystems for use with BOND Polymer Refine Detection and BOND ancillary reagents.
Users who deviate from recommended test procedures must accept responsibility for interpretation of patient results under these
circumstances. The protocol times may vary, due to variation in tissue fixation and the effectiveness of antigen enhancement, and must
be determined empirically. Negative reagent controls should be used when optimizing retrieval conditions and protocol times.
Troubleshooting
Refer to reference 3 for remedial action.
Contact your local distributor or the regional office of Leica Biosystems to report unusual staining.

Further Information

Further information on immunostaining with BOND reagents, under the headings Principle of the Procedure, Materials Required,
Specimen Preparation, Quality Control, Assay Verification, Interpretation of Staining, Key to Symbols on Labels, and General Limitations
can be found in "Using BOND Reagents" in your BOND user documentation.
Bibliography - General
1. Clinical Laboratory Improvement Amendments of 1988, Final Rule 57 FR 7163 February 28, 1992.
2. Villanova PA. National Committee for Clinical Laboratory Standards (NCCLS). Protection of laboratory workers from infectious
diseases transmitted by blood and tissue; proposed guideline. 1991; 7(9). Order code M29-P.
3. Bancroft JD and Stevens A. Theory and Practice of Histological Techniques. 4th Edition. Churchill Livingstone, New York. 1996.
4. Chen H, Xu C, Jin Q et al. S100 protein family in human cancer. American Journal of Cancer Research 2014;4(2):89-115
5. Torlakovic EE, Nielsen S, Francis G et al. Standardization of Positive Controls in Diagnostic Immunohistochemistry. Applied
Immunohistochemistry & Molecular Morphology. 2015; 23(1):1-18
Date of Issue
23 August 2019
PA0031
Page 3